Explore the promising potential of Altimmune, Inc.'s Pemvidutide in NASH, AUD, & obesity treatment, with key trials underway.

the Phase 2b trial in subjects with MASH; data readout expected in Q2 2025 GAITHERSBURG, Md., Nov. 15, 2024 (G Altimmune ( NASDAQ:ALT ) Third Quarter 2024 Results Key Financial Results Net loss ...

Altimmune plans Phase 2 trials in 2025 for pemvidutide in alcohol use disorder and liver disease, highlighting weight loss ...

Binance Coin (BNB) surges 15% following a $2 billion investment from MGX, boosting investor confidence and pushing BNB closer ...

The anticipated results from the IMPACT Phase 2b trial ... its ALT reduction aligns closely with the performance of competing therapies. I believe this will be one of the key biomarkers to be ...

In a key moment for the crypto industry’s recovery, FTX’s Bahamas wing will honor the first batch of repayments for users who are owed less than $50,000 worth of claims. Users will receive ...

As AI companies race to improve the accuracy of large language models (LLMs) and apps built on top of them, a startup that has emerged as a key partner in that effort is announcing a significant ...

[Fantasy Baseball Draft Rankings: C | 1B | 2B | 3B | SS | OF | SP | RP] At 32 years old, maybe his best days are behind him — or, maybe 2024 was an outlier, and Betts will once again be an ADP gift.

Chronic spontaneous urticaria is an idiopathic syndrome defined by recurring itch, hives, or angioedema (or a combination of ...